Skip to main content
Home / Experimental and Therapeutic Medicine, Volume 23, Number 6

Positive therapy outcome of lung squamous cell cancer: A case report

Buy Article:

$42.00 + tax (Refund Policy)

Authors: Liu 1 ; Yang 2 ; Sun 3 ; Lu 4 ; Liu 5 ; 

Source: Experimental and Therapeutic Medicine, Volume 23, Number 6, 2022, pp. 1-5(5)

Publisher: Spandidos Publications

DOI: https://doi.org/10.3892/etm.2022.11360

Abstract. Lung cancer is a rapidly progressing disease with a poor prognosis. Lung squamous cell cancer (LSCC) accounts for 2030% of lung cancer cases. Conventional chemotherapy and radiotherapy are the common options for LSCC. Nevertheless, the outcomes of these treatments are still unsatisfactory. The present report describes a rare case of LSCC with pericardial, cervical lymph node and extensive mediastinal lymph node metastases, who still survives today, in March 2022, more than 10 years after therapy and, therefore, this case study indicates a possible treatment regimen for patients with a similar condition. In conclusion, gemcitabine and cisplatin followed by radiotherapy were an effective treatment against pericardial and lymph node metastases from LSCC.

Document Type: Research Article

Affiliations: 1: Department of Medical Oncology, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China 2: Department of General Surgery, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154000, P.R. China 3: Department of Radiology Imaging, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China 4: Department of Ultrasonic Imaging, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China 5: Central Laboratory, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China

Publication date: 01 January 2022

More about this publication?
  • Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.

    All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content